Eli Lilly Updates 2024 Revenue Guidance and Announces 2025 Outlook

Details

For Q4 2024, the company expects revenue of approximately $13.5 billion, which is $400 million below the lower end of previous guidance. The company also announced its 2025 revenue guidance, anticipating sales to be in the range of $58.0 billion to $61.0 billion, with growth of 32% at the midpoint compared to expected 2024 revenue. These updates reflect strong performance in Lilly's incretin, oncology, immunology, and neuroscience segments, despite some challenges in channel inventory and market dynamics.

Items reported

Exhibits (1)

About Eli Lilly and Company

Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.